Scott Fung1, Peter Kwan2, Milotka Fabri3, Andrzej Horban4, Mijomir Pelemis5, Hie-Won Hann6, Selim Gurel7, Florin A Caruntu8, John F Flaherty9, Benedetta Massetto9, Kyungpil Kim9, Kathryn M Kitrinos9, G Mani Subramanian9, John G McHutchison9, Leland J Yee9, Magdy Elkhashab10, Thomas Berg11, Ioan Sporea12, Cihan Yurdaydin13, Petr Husa14, Maciej S Jablkowski15, Edward Gane16. 1. Department of Medicine, University of Toronto, Canada. Electronic address: scott.fung@uhn.ca. 2. Department of Medicine, University of British Columbia, Canada. 3. Clinic for Infectious Diseases, Medical University of Novi Sad, Serbia. 4. Department of Adult Infectious Diseases, Medical University of Warsaw, Poland. 5. Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Serbia. 6. Department of Medicine, Thomas Jefferson University, USA. 7. Department of Internal Medicine, Uludag University, Turkey. 8. National Institute for Infectious Diseases, "Prof Dr Matei Bals", Romania. 9. Gilead Sciences Inc, Foster City, CA, USA. 10. Toronto Liver Centre, Toronto, Canada. 11. Clinic of Gastroenterology and Rheumatology, University Hospital Leipzig, Germany. 12. University of Medicine and Pharmacy, Timisoara, Romania. 13. Department of Gastroenterology, Ankara University, Turkey. 14. University Hospital Brno and Faculty of Medicine, Masaryk University Brno, Czech Republic. 15. Department of Infectious and Liver Diseases, Medical University of Lodz, Poland. 16. New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand.
Abstract
BACKGROUND & AIMS: Long-term treatment with tenofovir disoproxil fumarate (TDF) alone, or in combination with emtricitabine (FTC) is associated with sustained viral suppression in patients with lamivudine resistant (LAM-R) chronic hepatitis B (CHB). METHODS:LAM-R CHB patients were randomised 1:1 to receive TDF 300mg or FTC 200mg and TDF 300mg once daily in a prospective, double blind, study. The proportion of patients with plasma hepatitis B virus (HBV) DNA<69IU/ml (<400copies/ml) at week 96 (primary efficacy endpoint) was reported previously. Here we present week 240 follow-up data. RESULTS: Overall, 280 patients were randomised to receive TDF (n=141) or FTC/TDF (n=139), and 85.4% completed 240weeks of treatment. At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96). Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively). Hepatitis Be antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively). Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240. No TDF resistance was observed up to week 240. Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%). The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively. CONCLUSIONS:TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240weeks. LAY SUMMARY: The goal of oral antiviral treatment for chronic hepatitis B (CHB) is to achieve and maintain undetectable HBV DNA levels. Treatment options with enhanced potency, and low risk of resistance development for patients infected with lamivudine resistant (LAM-R) HBV are required. Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks. Clinical trial number: NCT00737568. Copyright Â
RCT Entities:
BACKGROUND & AIMS: Long-term treatment with tenofovir disoproxil fumarate (TDF) alone, or in combination with emtricitabine (FTC) is associated with sustained viral suppression in patients with lamivudine resistant (LAM-R) chronic hepatitis B (CHB). METHODS:LAM-R CHB patients were randomised 1:1 to receive TDF 300mg or FTC 200mg and TDF 300mg once daily in a prospective, double blind, study. The proportion of patients with plasma hepatitis B virus (HBV) DNA<69IU/ml (<400copies/ml) at week 96 (primary efficacy endpoint) was reported previously. Here we present week 240 follow-up data. RESULTS: Overall, 280 patients were randomised to receive TDF (n=141) or FTC/TDF (n=139), and 85.4% completed 240weeks of treatment. At week 240, 83.0% of patients in the TDF arm, and 82.7% of patients in the FTC/TDF treatment arm had HBV DNA<69IU/ml (p=0.96). Rates of normal alanine aminotransferase (ALT) and normalised ALT were similar between groups (p=0.41 and p=0.97 respectively). Hepatitis B e antigen loss and seroconversion at week 240 were similar between groups, (p=0.41 and p=0.67 respectively). Overall, six patients achieved hepatitis B surface antigen (HBsAg) loss and one patient (FTC/TDF arm) had HBsAg seroconversion by week 240. No TDF resistance was observed up to week 240. Treatment was generally well tolerated, and renal events were mild and infrequent (∼8.6%). The mean change in bone mineral density at week 240 was -0.98% and -2.54% at the spine and hip, respectively. CONCLUSIONS:TDF monotherapy was effective and well tolerated in LAM-R CHB patients for up to 240weeks. LAY SUMMARY: The goal of oral antiviral treatment for chronic hepatitis B (CHB) is to achieve and maintain undetectable HBV DNA levels. Treatment options with enhanced potency, and low risk of resistance development for patients infected with lamivudine resistant (LAM-R) HBV are required. Tenofovir disoproxil fumarate (TDF) monotherapy was effective and well tolerated without TDF resistance development in CHB patients with LAM-R, for up to 240weeks. Clinical trial number: NCT00737568. Copyright Â
Authors: Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong Journal: Hepatology Date: 2018-04 Impact factor: 17.425
Authors: Andrea L Cathcart; Henry Lik-Yuen Chan; Neeru Bhardwaj; Yang Liu; Patrick Marcellin; Calvin Q Pan; Maria Buti; Stephanie Cox; Bandita Parhy; Eric Zhou; Ross Martin; Silvia Chang; Lanjia Lin; John F Flaherty; Kathryn M Kitrinos; Anuj Gaggar; Namiki Izumi; Young-Suk Lim Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191
Authors: Manuel Rodríguez; Juan Manuel Pascasio; Enrique Fraga; Javier Fuentes; Martín Prieto; Gloria Sánchez-Antolín; José Luis Calleja; Esther Molina; María Luisa García-Buey; María Ángeles Blanco; Javier Salmerón; María Lucía Bonet; José Antonio Pons; José Manuel González; Miguel Ángel Casado; Francisco Jorquera Journal: World J Gastroenterol Date: 2017-11-07 Impact factor: 5.742
Authors: Patricia Atencio; Francisco Miguel Conesa-Buendía; Alfonso Cabello-Ubeda; Patricia Llamas-Granda; Ramón Pérez-Tanoira; Laura Prieto-Pérez; Beatriz Álvarez Álvarez; Irene Carrillo Acosta; Rosa Arboiro-Pinel; Manuel Díaz-Curiel; Raquel Largo; Gabriel Herrero-Beaumont; Miguel Górgolas; Aránzazu Mediero Journal: Curr HIV Res Date: 2021 Impact factor: 1.341